Brain Organoids to Model Mitochondrial Neurological Diseases
Prof. Alessandro Prigione, ative member or WMS scientific committee, Heinrich Heine University (HHU) Düsseldorf, Germany, will join Targeting Mitochondria 2023 to present a talk entitled: "Brain Organoids to Model Mitochondrial Neurological Diseases".
Join Targeting Mitochondria 2023 to learn more about Prof. Prigione's interesting findings. You can submit a related abstract here.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Mitochondrial Monitoring in Perioperative and Critical Care: Recent Advances & Perspectives
Dr. Egbert Mik, Erasmus MC, The Netherlands, and ative member or WMS scientific committee, will be joining Targeting Mitochondria 2023. Dr. Mik will give an update on "Mitochondrial Monitoring in Perioperative and Critical Care"
In order not to miss this outstanding talk, so join Targeting Mitochondria 2023 to learn more about Dr. Mik's interesting findings.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Dr. Paul Hwang, Senior Investigator at the National Heart, Lung and Blood Institute, USA will present his latest finding targeting mitochondria in chronic fatigue symptoms during Targeting Mitochondria 2023 this October.
Dr. Hwang's talk will be titled: "WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in ME/CFS". He will share his latest findings reported in the Proceedings of the National Academy of Sciences. Read more about this outstanding publication.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disorder characterized by various disabling symptoms including exercise intolerance. Dr. Hwang and his team report that overexpression of Wiskott-Aldrich Syndrome Protein Family Member 3 (WASF3), here identified in a 38-y-old woman suffering from long-standing fatigue and exercise intolerance, can disrupt mitochondrial respiratory supercomplex formation.
Increased expression of WASF3 in transgenic mice decreased their treadmill running capacity and specific respiratory complexes. Expanding on our findings in a single patient, skeletal muscle biopsy samples obtained from a cohort of patients with ME/CFS showed increased WASF3 protein levels associated with aberrant ER stress activation. Pharmacologic inhibition of ER stress decreased WASF3 and improved mitochondrial function in the cells of the patient with chronic fatigue, suggesting a therapeutic strategy for ME/CFS treatment.
About Dr. Hwang
Dr. Paul Hwang earned B.A. degrees in biochemistry and chemistry from the University of Kansas in 1985, after which he spent a year at the Swiss Federal Institute of Technology and University of Zurich as a Fulbright Scholar. He graduated from the Johns Hopkins University School of Medicine with an M.D. and Ph.D in 1993. He did his internship and residency in internal medicine at the UCSF School of Medicine in San Francisco, followed by a clinical fellowship in cardiology and postdoctoral research in molecular oncology at the Johns Hopkins University School of Medicine. Upon completion of his training in 2001, Dr. Hwang joined the NHLBI-NIH as an investigator and was tenured in 2011. He has been elected as member of the American Society for Clinical Investigation and fellow of the American College of Cardiology.
Join Targeting Mitochondria 2023 to learn more about Dr. Hwang's research.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Metabolic effects of Cimicfuga racemosa extract on mitochondria and implications for the resistance against oxidative cell death and longevity
Prof. Carsten Culmsee, active member of the scientific committe and from the University of Marburg, Germany, will join Targeting Mitochondria 2023 this October. He will have a talk entitled "Metabolic effects of Cimicfuga racemosa extract on mitochondria and implications for the resistance against oxidative cell death and longevity".
Cimicifuga racemosa extract (CRE) is a well-established herbal medication to treat menopausal symptoms such as hot flashes and weight gain. In contrast to estrogen replacement therapy or phytoestrogens, however, CRE does not act through stimulation of estrogen receptors but through metabolic mechanisms. Prof. Culmsee and his team's findings suggest that CRE Ze 450 rather exerts direct effects on mitochondrial energy turnover through interference with components of the mitochondrial electron transport chain (ETC).
Prof. Culmsee will provide a comprehensive insight into the signalling effects of the extract on the mitochondrial proteome and metabolome, highlighting the role of CREe for the resilience against age-related processes engaging impaired mitochondria and loss of antioxidative capacities.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Vladimir Skulachev's Strategic Impact on Mitochondrial Medicine: A Tribute to his Vision, Discoveries, and Legacy
Prof. Vladimir Gogvadze, Karolinska Institutet, Sweden, and active member of the scientific committe will join Targeting Mitochondria 2023 this October and introduce the congress.
Prof. Gogvadze will dedicate his talk to Prof. Vladimir Skulachev, former member of the scientific committee of WMS, to recognize his impact in the Mitochondria World: "Vladimir Skulachev's Strategic Impact on Mitochondrial Medicine: A Tribute to his Vision, Discoveries, and Legacy".
Read more about Professor Skulachev's impact.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Advances in the Development of Mitochondria-Targeted Pharmaceuticals
Dr. Maxim Skulachev, CSO at Mitotech (Israel) , who manages Mitotech's core scientific research, will share the latest advances in developing mitochondria targeting drugs during Targeting Mitochondria 2023 this October.
In the last 15 years of his life and scientific career, Vladimir Skulachev dedicated himself to his project on practical application of penetrating ions. This ambitious endeavor focuses on developing new pharmaceuticals based on mitochondria-targeted antioxidants of the SkQ class.
Mitotech's leading compound, SkQ1, is currently undergoing extensive development for different indications and in various pharmaceutical forms, including eye drop formulations (which have reached the third stage of clinical trials in the US), as well as oral and injectable "systemic" formulations.
In this presentation, Dr. Skulachev would like to share their recent findings from preclinical studies they completed using the latter formulations, Mitotech team successfully harnessed both the antioxidant and mild uncoupling properties of SkQ1 molecule.
Dr. Skulachev's short talk will be titled: "Advances in the Development of Mitochondria-Targeted Pharmaceuticals".
Read more about Professor Vladimir Skulachev's impact.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
What spaceflight and bed rest have in common: A proteomic point of view
Dr. Marta Murgia from the University of Padova, Italy will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "What spaceflight and bed rest have in common: A proteomic point of view".
In the absence of mechanical loading, skeletal muscle undergoes atrophy with loss of strength and detrimental metabolic effects. Dr. Murgia and her team used highly sensitive mass spectrometry (MS)-based proteomics to detail single fiber type-specific molecular remodeling caused by muscle unloading, using bed rest as a model.
In parallel, they measured the muscle proteome of two astronauts, from biopsies taken before and after a six months mission on the International Space Station (ISS). In their muscle lysates, they measured a sharp decrease in the expression of the whole mitochondrial proteome.
Dr. Murgia's talk will give an overview of the main proteomic changes that we measured in these two different models of muscle unloading and disuse. She will highlight striking similarities as well as profound differences. She will discuss the protective role of exercise on skeletal muscle mass in space, with a focus on the mitochondrial proteome.
Join Targeting Mitochondria 2023 to learn more about Dr. Murgia's exciting talk. You can submit a related abstract here.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Mitochondria Organelle Transplantation for Neurological Diseases & Aging
Dr. Mark S. Kindy from the University of South Florida, USA, will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "Mitochondria Organelle Transplantation for Neurological Diseases and Aging".
Join Targeting Mitochondria 2023 to learn more about Dr. Kindy's exciting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
